The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis

The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: زینب نیک نیاز , کوروش مسندی شیرازی , آرمان مسندی شیرازی نژاد , یاسمن حسین زاده , زهرا نورپناه

کلمات کلیدی: CA19-9, primary sclerosing cholangitis, ulcerative colitis

نشریه: 0 , 0 , 0 , 2019

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله زینب نیک نیاز
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های گوارش و کبد
کد مقاله 71362
عنوان فارسی مقاله The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis
عنوان لاتین مقاله The value of serum CA19-9 in predicting primary sclerosing cholangitis in patients with ulcerative colitis
ناشر 5
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ خیر
عنوان نشریه (خارج از لیست فوق) advances in digestive medicine
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

In the present study, we postulated that using CA19-9 in inflammatory bowel disease (IBD) patients may be a useful method for the screening of primary sclerosing cholangitis (PSC). Considering the presence of other extraintestinal manifestations (EIMs) in IBD such as arthritis that may associate with the elevated level of CA19-9, in the present study we aimed to compare the CA19-9 level in ulcerative colitis (UC) patients with PSC or other EIMs and also evaluate the value of CA19-9 in the detection of PSC in UC patients. In the present cross-sectional study, 192 patients with UC were selected. EIMs were diagnosed based on patients recall and after a thorough physical examination. PSC was diagnosed by magnetic resonance cholangiopancreatography by expert gastroenterologist and radiologist. Serum level of CA19-9 was measured using chemiluminescent enzyme immunometric assay. About 6.77% of participants had PSC and 24.47% of them had other EIMs. The results showed that the CA19-9 level in patients with PSC (median [interquartile range (IQR)]: 93 [10-125]) was significantly higher than that of patients diagnosed with other EIMs (median [IQR]: 11 [6-17.30]) or with no EIMs (median [IQR]: 7.15 [4.82-11.00]). CA19-9 value of >75 U/mL could predict PSC by the sensitivity of 69% and specificity of 99% with an area under the ROC curve (AUC) of 0.83 in UC patients and alkaline phosphatase (ALP) > 299.5 could predict PSC with a sensitivity of 100% and a specificity of 99% and AUC of 0.99. In addition, 23.07% of PSC patients had CA19-9 level of >129 U/ mL. According to the results, ALP had higher sensitivity and specificity for the screening of PSC compared to CA19-9 in UC patients. Moreover, 23.07% of PSC patients had CA19-9 level of >129 U/mL. So it could be concluded that cut-off of >129 U/mL may not be an accurate cut-off for the diagnosis of CCA in IBD patients.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
زینب نیک نیازپنجم
کوروش مسندی شیرازیاول
آرمان مسندی شیرازی نژادچهارم
یاسمن حسین زادهدوم
زهرا نورپناهسوم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
ca19 pac.pdf1398/12/14774280دانلود